Safety and Tolerability of Single and Repeated Doses of ODM-203: An Open-label, Non-randomised, Uncontrolled, Dose Escalation, Multicentre, First-in-Human Study in Subjects With Advanced Solid Tumours

Trial Profile

Safety and Tolerability of Single and Repeated Doses of ODM-203: An Open-label, Non-randomised, Uncontrolled, Dose Escalation, Multicentre, First-in-Human Study in Subjects With Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs ODM 203 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms KIDES-203
  • Sponsors Orion
  • Most Recent Events

    • 11 Oct 2016 Results (n=31) presented at the 41st European Society for Medical Oncology Congress
    • 07 Jun 2016 Results (n=24) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 02 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top